GlassScriptPhysician profile
Christopher James Turner
NPI 1194728113
$2,146.62
in general payments reported to CMS, 2019-2025
17 companies · $559 in 2025
The $559 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $92.05 · 2021: $102 · 2022: $175 · 2023: $520 · 2024: $384 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $540.44 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Abbvie INC. | $475.30 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Dompe US, INC. | $176.24 | 2023-2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $161.89 | 2020-2025 | Cequa |
| Alcon Vision LLC | $133.09 | 2019-2025 | Eysuvis, Precision7, Clareon Panoptix Pro |
| Rxsight INC | $120.64 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Allergan, INC. | $102.28 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $100.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $56.00 | 2019 | |
| Amgen INC. | $53.68 | 2024 | Tepezza |
| Thea Pharma INC. | $49.93 | 2022-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $47.40 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.89 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.88 | 2019 | |
| Rayner Intraocular Lenses Limited | $24.02 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $18.76 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $17.20 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.